ATS 2019 Virtual Final Program

The annual Clinical Year in Review symposia provides concise summaries of the most impactful clinical research publications related to specific clinical topics. Speakers are asked to conduct a literature review of the prior year’s scientific publications and develop a written summary of the top 20 articles and highlight 5 of the most important and influential publications on their topic in written format and during their talks at the International Conference Clinical Year in Review sessions. Chairing: V.E. Ortega, MD, PhD, ATSF, Winston Salem, NC J.S. Lee, MD, Aurora, CO P.A. Kritek, MD, EdM, Seattle, WA 9:15 Lung Cancer S. Janes, PhD, London, United Kingdom 9:44 Palliative Medicine R. Aslakson, MD, PhD, Stanford, CA 10:13 Update on Pulmonary Vascular Diseases V. De Jesus Perez, MD, ATSF, Palo Alto, CA 10:42 Medical Education P.H. Lenz, MD, MEd, Cincinnati, OH 11:11 MOC Questions This session and the International Conference are supported by educational grants from AstraZeneca LP, Bayer US. All CME sessions have been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) and are free of the control of commercial interests. CLINICAL CLINICAL TOPICS IN PULMONARY MEDICINE CME Credits Available: 2 D2 STATE OF THE ART PLEURAL DISEASE MANAGEMENT: CLINICAL TRIALS CHANGING CARE PRACTICE Assembly on Clinical Problems 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom C One-Two (Level 2) Target Audience Clinicians and allied health professionals with clinical and/or research responsibilities in respiratory diseases; chest physicians, interventional pulmonologists, oncologists, nurses, thoracic surgeons, internists, GPs, emergency physicians. Objectives At the conclusion of this session, the participant will be able to: • review the latest clinical trial evidence on best management of malignant pleural effusions, especially regarding the use of indwelling pleural catheters vs/plus pleurodesis; highlighting recently practice changing trials in the field; • understand and review the latest clinical trial evidence on best management of pleural infection, especially intrapleural therapy with tPA DNase, and the ongoing work on their best delivery regimes; • understand the latest research finding spontaneous pneumothorax management. The last two years have seen many multicentered pleural disease trials completed with major impact on clinical care. These studies have been published in high impact journals: including trials on malignant effusions (especially IPC-PLUS in NEJM 2018; AMPLE-1 in JAMA 2017 and TIME-1 and -2 trials both in JAMA), mesothelioma (SMART trial in Lancet Oncol 2017; MAPPs and Meso-VATS in Lancet) etc. Several large trials eg the AMPLE-2 (under revision), PLEASE, PSP (pneumothorax), TAPPS etc have completed enrollment and will report results in 2018/early 2019. The proposed session will update the audience of the latest exciting advances from RCTs that impact care. In addition, large prognostic series for pleural infection (PILOT) and malignancies (LENT, PROMISE) can inform clinicians in practice. This has prompted a recent review of pleural diseases in NEJM 2018. Chairing: C. Broaddus, MD, San Francisco, CA H. Davies, MD, Cardiff, United Kingdom 9:15 Practice Changing Clinical Trials in Pneumothorax E. Ball, MBBS, Hobart, Australia 9:40 State of the Art Management of Pleural Infection D.J. Feller-Kopman, MD, Baltimore, MD 10:05 Management of Tuberculous Pleural Effusions C.F.N. Koegelenberg, MD, PhD, Cape Town, South Africa 10:25 Practice Changing Clinical Trials in Malignant Pleural Effusions Y.C.G. Lee, MBChB, PhD, Perth, Australia 10:50 State of the Art Prognostic Tools for Pleural Infection and Malignancies I. Psallidas, MD, PhD, Oxford, United Kingdom CLINICAL CLINICAL TOPICS IN PULMONARY MEDICINE CME Credits Available: 2 MOC Points Available: 2 D3 RURALITY IN COPD: DEFINING THE PROBLEM AND DEPLOYING NOVEL CARE DELIVERY APPROACHES Assemblies on Clinical Problems; Environmental, Occupational and Population Health 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom C Three-Four (Level 2) Target Audience Healthcare professionals of all backgrounds caring for patients with COPD or practicing in a rural environment Objectives At the conclusion of this session, the participant will be able to: • improve diagnosis of COPD in rural patients through understanding of specific epidemiological and environmental risk factors; • improve the care of rural COPD patients by identifying barriers to healthcare delivery in this population; • consider innovative care delivery techniques when discussing treatment options with rural COPD patients. Chronic obstructive pulmonary disease (COPD) leads to more respiratory symptoms, healthcare utilization, and mortality among rural patients compared to their urban counterparts. Unique environmental exposures and poorer access ATS 2019 • Dallas, TX WEDNESDAY • MAY 22 313 WEDNESDAY MORNING